Would you like to see your presentation here, made available to a global audience of researchers?
Add your own presentation or have us affordably record your next conference.
Choline, a vital nutrient essential for cognitive functions, including memory, executive functions, and learning. Humans obtain choline from two sources: dietary intake and hepatic biosynthesis. The biosynthesis of choline is regulated by estrogen which diminished with ageing, impacting post-menopausal women. However, the recent NHANES shows only 2% of post-menopausal women in the U.S. meet the adequate intake (AI) of choline, highlighting the critical need for a novel ingredient to increase choline consumption. We hypothesize Whey Protein Phospholipid Concentrate (WPPC), a byproduct of cheese processing, is a bioavailable and safe source of choline because of its richness of choline precursors phosphatidylcholine (PC) and unique triple-layered phospholipid structure. To test this hypothesis, we will conduct a single-blinded parallel designed randomized control trial in post-menopausal women. The changes in serum choline metabolites after WPPC intervention will be measured by UHPLC-HRMS/MS as the primary outcome. The safety of WPPC consumption will be determined by dissecting the changes in detrimental metabolites of choline, trimethylamine (TMA) and its oxidized product (TMAO), using UHPLC-HRMS/MS, and alteration of oxidative stress and proinflammatory biomarkers, such as 8-hydroxydeoxyguanosine, IL-1, IL-6, TNF-a, and hsCRP by utilizing ELISA and immunoturbidimetry. Lastly, the abundance and diversity of gut microbes will be measured using 16S rRNA sequencing to explore the impacts of WPPC on cognition-related microbe populations. Our findings will demonstrate the safety and bioavailability profile of WPPC and its application in supplementing choline intake in post-postmenopausal women. The valuable clinical data will support the establishment of a Recommended Daily Allowance (RDA) for choline.
